Richard T Silver

Richard T Silver

UNVERIFIED PROFILE

Are you Richard T Silver?   Register this Author

Register author
Richard T Silver

Richard T Silver

Publications by authors named "Richard T Silver"

Are you Richard T Silver?   Register this Author

89Publications

1802Reads

12Profile Views

Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension.

J Am Soc Echocardiogr 2019 Oct 3. Epub 2019 Oct 3.

Greenberg Cardiology Division, Department of Medicine, Weill Cornell Medical College, New York, New York; Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.echo.2019.07.010DOI Listing
October 2019

Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera.

Leuk Lymphoma 2017 11 20;58(11):2768-2769. Epub 2017 Mar 20.

b Wessex Regional Genetics Laboratory , Salisbury District Hospital , Salisbury , UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1300892DOI Listing
November 2017

Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients.

Haematologica 2017 03 3;102(3):e97-e99. Epub 2016 Nov 3.

Richard T. Silver Center for Myeloproliferative Neoplasms, Division of Hematology/Medical Oncology, Weill Cornell Medicine, New York, NY, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2016.153973DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394963PMC
March 2017

Management of CML-blast crisis.

Best Pract Res Clin Haematol 2016 09 20;29(3):295-307. Epub 2016 Oct 20.

Division of Hematology/Medical Oncology, Weill Cornell Medical College, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2016.10.005DOI Listing
September 2016

Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials.

Hematology 2016 Aug 26;21(7):387-91. Epub 2016 Feb 26.

b Department of Hematology , Roskilde Hospital, University of Copenhagen , Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10245332.2015.1111644DOI Listing
August 2016

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

J Natl Cancer Inst 2016 Jul 4;108(7). Epub 2016 Mar 4.

Affiliations of authors:Department of Health Policy and Management, Johns Hopkins University , Baltimore, MD (WVP); Department of Medicine (RAL) and Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL; Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center , and Cecil G. Sheps Center for Health Services Research, University of North Carolina , Chapel Hill, NC (SBD); Department of Haematology, Hammersmith Hospital, Imperial College , London , UK (JFA); Department of Medicine (RH, SS) and Department of Hematology and Oncology (MCM), University of Heidelberg, Mannheim, Germany; Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and Department of Hematology, "L. e A. Seragnoli" (GM), University of Bologna , Bologna , Italy ; Department of Haematology and Oncology, University Hospital , Jena , Germany (EE); INSERM Centre d'Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG); Laboratoire d'Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France (FXM); Department of Internal Medicine, Hematology and Oncology, University Hospital Brno , Brno , Czech Republic (JM); Department of Hematology and Oncology, University Hospital Leipzig , Leipzig , Germany (DN); Barbara Ann Karmanos Cancer Institute, Wayne State University , Detroit, MI (CAS); Department of Medicine, Weill Cornell Medical Center , New York, NY (RTS); Uppsala University , Uppsala , Sweden (BS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948567PMC
July 2016

Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.

Clin Lymphoma Myeloma Leuk 2016 May 18;16(5):297-303. Epub 2016 Feb 18.

Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY; New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.02.004DOI Listing
May 2016

Strategies that delay or prevent the timely availability of affordable generic drugs in the United States.

Blood 2016 Mar 27;127(11):1398-402. Epub 2016 Jan 27.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX; Baker Institute, Rice University, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-11-680058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915805PMC
March 2016

Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response.

Mod Pathol 2015 Oct 14;28(10):1315-23. Epub 2015 Aug 14.

Hematopathology Division, Department of Pathology and Laboratory Medicine, New York Presbyterian/Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/modpathol201593
Publisher Site
http://dx.doi.org/10.1038/modpathol.2015.93DOI Listing
October 2015

Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?

Expert Rev Hematol 2015 Aug 21;8(4):439-45. Epub 2015 May 21.

Department of Hematology, Roskilde Hospital, University of Copenhagen, Roskilde, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2015.1045409DOI Listing
August 2015

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:
Ayalew Tefferi Hagop Kantarjian S Vincent Rajkumar Lawrence H Baker Jan L Abkowitz John W Adamson Ranjana Hira Advani James Allison Karen H Antman Robert C Bast John M Bennett Edward J Benz Nancy Berliner Joseph Bertino Ravi Bhatia Smita Bhatia Deepa Bhojwani Charles D Blanke Clara D Bloomfield Linda Bosserman Hal E Broxmeyer John C Byrd Fernando Cabanillas George Peter Canellos Bruce A Chabner Asher Chanan-Khan Bruce Cheson Bayard Clarkson Susan L Cohn Gerardo Colon-Otero Jorge Cortes Steven Coutre Massimo Cristofanilli Walter J Curran George Q Daley Daniel J DeAngelo H Joachim Deeg Lawrence H Einhorn Harry P Erba Francisco J Esteva Elihu Estey Isaiah J Fidler James Foran Stephen Forman Emil Freireich Charles Fuchs James N George Morie A Gertz Sergio Giralt Harvey Golomb Peter Greenberg Jordan Gutterman Robert I Handin Samuel Hellman Paulo Marcelo Hoff Ronald Hoffman Waun Ki Hong Mary Horowitz Gabriel N Hortobagyi Clifford Hudis Jean Pierre Issa Bruce Evan Johnson Philip W Kantoff Kenneth Kaushansky David Khayat Fadlo R Khuri Thomas J Kipps Margaret Kripke Robert A Kyle Richard A Larson Theodore S Lawrence Ross Levine Michael P Link Scott M Lippman Sagar Lonial Gary H Lyman Maurie Markman John Mendelsohn Neal J Meropol Yoav Messinger Therese M Mulvey Susan O'Brien Roman Perez-Soler Raphael Pollock Josef Prchal Oliver Press Jerald Radich Kanti Rai Saul A Rosenberg Jacob M Rowe Hope Rugo Carolyn D Runowicz Brenda M Sandmaier Alan Saven Andrew I Schafer Charles Schiffer Mikkael A Sekeres Richard T Silver Lillian L Siu David P Steensma F Marc Stewart Wendy Stock Richard Stone Rainer Storb Louise C Strong Martin S Tallman Michael Thompson Naoto T Ueno Richard A Van Etten Julie M Vose Peter H Wiernik Eric P Winer Anas Younes Andrew D Zelenetz Charles A LeMaistre

Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365030PMC
August 2015

The hematocrit value in polycythemia vera: caveat utilitor.

Leuk Lymphoma 2015 May 30;56(5):1540-1. Epub 2014 Oct 30.

Division of Hematology/Medical Oncology, Weill Cornell Medical College , New York, NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.966243DOI Listing
May 2015

Management of chronic myeloid leukemia in blast crisis.

Ann Hematol 2015 Apr 27;94 Suppl 2:S159-65. Epub 2015 Mar 27.

III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Pettenkoferstr. 22, 68169, Mannheim, Germany,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-015-2324-0DOI Listing
April 2015

Life, genes, and death in Ph- MPNs.

Authors:
Richard T Silver

Blood 2014 Oct;124(16):2471-2

WEILL CORNELL MEDICAL COLLEGE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-08-590364DOI Listing
October 2014

Ruxolitinib for myelofibrosis--an update of its clinical effects.

Clin Lymphoma Myeloma Leuk 2013 Dec 2;13(6):638-45. Epub 2013 Oct 2.

University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.09.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556922PMC
December 2013

Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis.

Blood 2013 Sep 30;122(11):1881-6. Epub 2013 Jul 30.

Division of Hematology and Medical Oncology, Department of Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-06-508416DOI Listing
September 2013

Are all interferons the same for therapy in polycythemia vera?

Authors:
Richard T Silver

Clin Lymphoma Myeloma Leuk 2013 Sep;13 Suppl 2:S305-6

Myeloproliferative Disease Center, Division of Hematology-Oncology, Weill Cornell Medical Center, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650130023
Publisher Site
http://dx.doi.org/10.1016/j.clml.2013.05.016DOI Listing
September 2013

Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.

Expert Rev Hematol 2013 Feb;6(1):49-58

Myeloproliferative Disease Center, Division of Hematology-Oncology, Weill Cornell Medical Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.12.69DOI Listing
February 2013

Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.

Haematologica 2012 Apr 18;97(4):538-42. Epub 2011 Nov 18.

Weill Cornell Medical College, Department of Medicine, Division of Hematology and Medical Oncology, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2011.053348DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347655PMC
April 2012

Treatment of polycythemia vera with imatinib mesylate.

Leuk Res 2012 Feb 7;36(2):156-62. Epub 2011 Oct 7.

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065-4896, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2011.09.001DOI Listing
February 2012

Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?

Authors:
Richard T Silver

Oncologist 2011 30;16(5):554-8. Epub 2011 Mar 30.

Weill Cornell Medical College, Department of Medicine, Division of Hematology and Medical Oncology, New York, New York 10065-4896, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2010-0297DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228184PMC
September 2011

The treatment of essential thromobocytosis revisited.

Blood 2011 Jul;118(4):1179-80; author reply 1180-1

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2011-03-341925DOI Listing
July 2011

Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report.

Blood 2011 Jun 25;117(24):6669-72. Epub 2011 Apr 25.

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, 1305 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2010-11-32
Publisher Site
http://dx.doi.org/10.1182/blood-2010-11-320069DOI Listing
June 2011

JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy.

Leuk Res 2011 Feb 22;35(2):177-82. Epub 2010 Jul 22.

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065-4896, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126100030
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2010.06.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626091PMC
February 2011

Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia.

Clin Lymphoma Myeloma Leuk 2010 Oct;10(5):331-5

SAN GmbH, Reiden, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLML.2010.n.065DOI Listing
October 2010

The blast phase of chronic myeloid leukaemia.

Authors:
Richard T Silver

Best Pract Res Clin Haematol 2009 Sep;22(3):387-94

Department of Medicine, Division of Hematology & Medical Oncology, Leukemia and Myeloproliferative Center, Weill Cornell Medical College, 525 East 68th Street, Box 581, Payson Pavilion, 3rd Floor, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2009.07.006DOI Listing
September 2009

The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal.

Blood 2008 Jul 9;112(2):231-9. Epub 2008 Apr 9.

Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2007-12-128454DOI Listing
July 2008

Polycythemia vera and other polycythemia syndromes.

Authors:
Richard T Silver

Cancer Treat Res 2008 ;142:1-27

Weill Cornell Medical University, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-0-387-73744-7_1DOI Listing
March 2008

Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera.

Clin Immunol 2007 Mar 17;122(3):279-87. Epub 2006 Nov 17.

Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clim.2006.10.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2637448PMC
March 2007

Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate.

Authors:
Richard T Silver

Curr Hematol Malig Rep 2007 Feb;2(1):43-6

New York-Presbyterian Hospital/Weill Cornell Medical Center, 1300 York Avenue, Box 581, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-007-0006-2DOI Listing
February 2007

Characterization of murine JAK2V617F-positive myeloproliferative disease.

Cancer Res 2006 Dec;66(23):11156-65

Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-06-2210DOI Listing
December 2006

Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha.

Authors:
Richard T Silver

Cancer 2006 Aug;107(3):451-8

Division of Hematology-Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.22026DOI Listing
August 2006

Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.

N Engl J Med 2006 Aug;355(7):737; author reply 738

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc061631DOI Listing
August 2006

Treatment of polycythemia vera.

Authors:
Richard T Silver

Semin Thromb Hemost 2006 Jun;32(4 Pt 2):437-42

Division of Hematology-Oncology, New York Presbyterian-Weill Cornell Medical Center, New York, New York 10021-4873, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-2006-942765DOI Listing
June 2006

Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate.

Authors:
Richard T Silver

Curr Hematol Rep 2005 May;4(3):235-7

New York Presbyterian-Weill Cornell Medical Center, 1300 York Avenue, Box 581, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
May 2005

Ex vivo evaluation of erythrocytosis-enhanced platelet thrombus formation using the cone and plate(let) analyzer: effect of platelet antagonists.

Br J Haematol 2004 Oct;127(2):195-203

Department of Pathology, Weill Medical College of Cornell University, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2004.05190.xDOI Listing
October 2004

Myelofibrosis: thalidomide finds a new disease.

Authors:
Richard T Silver

Mayo Clin Proc 2004 Jul;79(7):857-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4065/79.7.857DOI Listing
July 2004

Imatinib mesylate in polycythemia vera.

Blood 2004 Apr;103(8):3241; author reply 3241-2

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2003-12-4248DOI Listing
April 2004

Chronic myeloid leukemia.

Authors:
Richard T Silver

Hematol Oncol Clin North Am 2003 Oct;17(5):1159-73, vi-vii

Weill Cornell Medical College, 525 East 68th Street, Box 581, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
October 2003

The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate.

Exp Hematol 2003 Aug;31(8):702-7

The Leukemia and Myeloproliferative Center, Weill Medical College of Cornell University, New York, NY, USA.

View Article

Download full-text PDF

Source
August 2003

A hope for the future.

Authors:
Richard T Silver

Cancer Invest 2003 Jun;21(3):486

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1081/cnv-120018243DOI Listing
June 2003

Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia.

Cancer Genet Cytogenet 2002 Sep;137(2):79-84

North Shore-Long Island Jewish Research Institute, Manhasset, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0165-4608(02)00558-7DOI Listing
September 2002

Treatment of polycythemia vera with recombinant interferon.

Authors:
Richard T Silver

Int J Hematol 2002 Aug;76 Suppl 2:294-5

Department of Medicine Cornell University, New York Presbyterian Hospital, NY, USA.

View Article

Download full-text PDF

Source
August 2002